



Published in final edited form as:

Wiley Interdiscip Rev RNA. 2017 July ; 8(4): . doi:10.1002/wrna.1413.

RNA in extracellular vesicles

Kyoung Mi Kim^{1,#}, Kotb Abdelmohsen¹, Maja Mustapic², Dimitrios Kapogiannis², and Myriam Gorospe¹


¹Laboratory of Genetics and Genomics, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA

²Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA

Abstract

Cells release a range of membrane-enclosed extracellular vesicles (EVs) into the environment. Among them, exosomes and microvesicles (collectively measuring 30-1000 nm in diameter) carry proteins, signaling lipids, and nucleic acids from donor cells to recipient cells, and thus have been proposed to serve as intercellular mediators of communication. EVs transport cellular materials in many physiologic processes, including differentiation, stem cell homeostasis, immune responses, and neuronal signaling. EVs are also increasingly recognized as having a direct role in pathological processes, notably cancer and neurodegeneration. Accordingly, EVs have been the focus of intense investigation as biomarkers of disease and prognostic indicators, and even therapeutic tools. Here, we review the classes of RNAs present in EVs, both coding RNAs (mRNAs) and noncoding RNAs (long noncoding RNAs, microRNAs, and circular RNAs). The rising attention to EV-resident RNAs as biomarkers stems from the fact that RNAs can be detected at extremely low quantities using a number of methods. To illustrate the interest in EV biology, we discuss EV RNAs in cancer and neurodegeneration, two major age-associated disease processes.

Graphical abstract



[#]Correspondence: Kyoung Mi Kim, Laboratory of Genetics and Genomics, National Institute on Aging, National Institutes of Health, 251 Bayview Blvd. Baltimore, MD 21224, USA, Tel: +1 410 558 8216; Fax: +1 410 558 8331, kyoungmi.kim@nih.gov.

CONFLICTS OF INTEREST

The authors have no conflicts of interest.

Keywords

Extracellular vesicle; exosome; microvesicle; microRNA; long noncoding RNA; circular RNA; biomarker; gene therapy; drug delivery

INTRODUCTION

Extracellular Vesicles

Cells produce extracellular vesicles (EVs) of three main types, according to their size and biogenesis: exosomes, microvesicles, and apoptotic bodies.¹⁻⁴ Microvesicles, measuring 0.2-1 μm in diameter, arise through budding of the plasma membrane and are therefore enclosed by a fraction of plasma membrane.^{5, 6} Apoptotic bodies are released from blebbing of the plasma membrane of apoptotic cells and have diameters of 0.5-2 μm .^{7, 8} Exosomes, by contrast, arise from the endosomal pathway and form intracellular multivesicular bodies (MVBs) which fuse to the plasma membrane and are secreted as vesicles measuring 0.04-0.1 μm . EVs were first described by Pan *et al.* and Johnstone *et al.* in 1983 in sheep reticulocytes and were subsequently visualized using electron microscopy (EM)^{9, 10, 11} EVs are secreted from numerous cell types and have been isolated from a wide variety of human body fluids such as blood, urine, saliva, and breast milk.¹²⁻¹⁵

A variety of molecules have been identified in EVs, including DNA, RNA, bioactive lipids, and proteins.¹⁶ These molecules are protected by EV membranes from nucleases, proteases, fluctuations in pH and osmolarity, and other environmental factors.¹⁷⁻²⁰ EV components can be delivered from an originating cell to a recipient cell, whether the recipient cell is in the vicinity (horizontal transfer) or in a distant tissue, and the transferred molecules are capable of eliciting changes in function and gene expression in the recipient cell.²⁰⁻²² Since EVs are found in easily accessible body fluids, particularly blood, they are attractive sources of diagnostic and prognostic biomarkers.^{23, 24} In addition, since EVs are derived from intracellular material, they are being explored as packaging tools for the therapeutic delivery of genetic material and drugs.²⁵⁻²⁹ As we gain more information about EVs directed to specific tissues and organs, such delivery of therapeutic molecules could be targeted with high precision.³⁰ Given the rising interest in exploiting EVs in disease diagnosis and treatment, there is urgency to determine comprehensively the tissues of origin of EVs, their target tissues, and their molecular constituents. Towards the latter goal, the relatively low abundance of EVs presents some challenges, but highly sensitive methods of RNA detection developed in recent years [particularly RNA-sequencing (RNA-Seq) and reverse transcription and quantitative PCR analysis (RT-qPCR)] afford accurate and quantitative identification of RNAs, even if present in very low amounts. In this review, we discuss the progress made by the RNA and EV communities to identify the pools of transcripts present in exosomes and microvesicles.

DIVERSE RNAs IN EVs

The identification of RNAs in EVs has progressed immensely in recent years thanks to technical advances in the detection of low-abundance, complex RNA samples. RNA pools in

EVs have been identified comprehensively using high-throughput RNA-Seq and many have been validated using RT-qPCR analysis. These RNA populations include various protein-coding transcripts (mRNAs) and many types of non-coding RNAs, including microRNAs (miRNA), long noncoding RNAs (lncRNAs), circular RNAs (circRNAs), small nucleolar RNA (snoRNAs), small nuclear RNAs (snRNAs), transfer RNA (tRNAs), ribosomal RNAs (rRNAs), and piwi-interacting RNAs (piRNAs).³¹ These RNAs can be transferred from parent cells to recipient cells, where they can regulate or serve as templates for protein production,^{32, 33} although the relative abundance of full-length and fragmented transcripts in EVs is not known at present because the analysis methods available (RNA-Seq and microarray) identify relatively small RNA segments. In this review, we focus on mRNAs, microRNAs, lncRNAs, and circRNAs identified in EVs.

Protein-coding RNA (mRNA)

Protein-coding RNAs are synthesized in the nucleus as pre-mRNAs and then typically undergo splicing, modification of the ends, and export to the cytosol, where they function as templates for protein translation. mRNAs have three basic segments, the 5'-untranslated region (5' UTR), the coding region (CR, which encodes protein), and the 3' UTR. A number of reports have identified full-length and sometimes fragmented mRNAs in EVs. For example, early microarray analysis revealed that EVs (primarily exosomes) derived from glioblastoma cells contained 27,000 mRNAs.²⁰ Interestingly, ~4,700 of these mRNAs were only detected in EVs, not in cells, and >3,000 mRNAs were preferentially included (2,238 mRNAs) or excluded (1,188 mRNAs) from EVs compared with mRNAs found in cells. To test whether mRNAs in glioblastoma-produced EVs were translated in recipient cells, the authors expressed *Gaussia* luciferase⁴ (*Gluc*) mRNA in glioblastoma cells and purified EVs from the medium. *Gluc* mRNA encodes a luciferase protein that is secreted and emits intense fluorescence. They then added these EVs to recipient human brain microvascular endothelial cells (HBMVECs) and found that *Gluc* activity released by HBMVECs increased continuously over the ensuing 24 h. These findings supported the view that the cargo *Gluc* mRNA from the parent cell was translated in the recipient cell to generate a functional protein. These results contribute to a substantial body of evidence that EV-resident mRNAs can be translated in recipient cells.

Another study used microarrays to identify 13,000 mRNAs in EVs derived from MC/9 cells (a mouse mast cell line).³⁴ Interestingly, 270 mRNAs were only detected in EVs and not in cells. To test if the EV mRNAs could serve as a templates for the synthesis of functional proteins, they used rabbit reticulocyte lysate as an *in vitro* translation system. Following the completion of translation, two-dimensional polyacrylamide gel electrophoresis was employed to identify mouse proteins (COX5B, HSPA8, SHMT1, LDH1, ZFP125, GPI1, and RAD23B) from rabbit proteins by mass spectrometry analysis. The authors concluded that many EV-resident mRNAs were translated efficiently.

In another model system, human central nervous system (CNS)-patrolling macrophages, stimulation by β -amyloid peptide (A β) resulted in the secretion of exosomes containing a number of cytokine mRNAs relevant to Alzheimer's disease (AD) pathogenesis. Interestingly, macrophages derived from older subjects generated higher levels of exosomal

IL6, *TNF*, and *IL12* mRNAs, but did not exhibit differences in the levels of *IL8*, *IL1*, or *IL23* mRNAs. The authors proposed that cytokine mRNAs in exosomes may be a mechanism for spreading neuroinflammation induced by A β peptide.³⁵ In sum, many mRNAs residing in EVs can be translated and contribute to the protein expression programs of recipient cells.

microRNA (miRNA)

MicroRNAs are small (~22-nt) non-coding, highly conserved, single-stranded RNAs found both inside and outside of cells.^{36, 37} The biosynthesis of microRNAs begins with the transcription of a primary (pri-) microRNA that is processed by the RNase III DROSHA into a ~70 nucleotide stem-loop transcript, the precursor (pre-)microRNA. XPO5 (Exportin-5) then exports pre-microRNAs to the cytoplasm where they are processed by RNase III DICER1 into mature ~22-nt microRNA duplexes;^{37, 38} after unwinding the duplex, one strand associates with AGO (Argonaute) proteins to form RNA-induced silencing complex (RISC).^{36, 38, 39} Alternative pathways for microRNA biogenesis have also been described.⁴⁰ Although microRNAs can affect gene transcription by influencing chromatin structure and transcription, they are best known for eliciting gene silencing by lowering the stability and/or translation of mRNAs with which they share partial complementarity, generally at the mRNA 3' UTR.^{36, 41, 42} By modulating gene expression programs in the cells in which they are generated, microRNAs play a role in a wide range of biological processes, including development, cell proliferation and differentiation, apoptosis, and immune regulation.⁴¹

MicroRNAs can also participate in intercellular signaling. Many body fluids harbor abundant, stable microRNAs which avoid nucleolytic degradation by associating with RNA-binding proteins (RBPs) and high- and low-density lipoproteins, and by being encapsulated in EVs.⁴³⁻⁴⁵ With the discovery of microRNAs in EVs, many new functions and applications have emerged – from new ways of cell-cell communication to potentially easy-access biomarkers and, given the non-immunogenicity of EVs, possibly novel therapeutics.^{19, 46-51} MicroRNAs uptaken via EVs might function as gene expression regulators in recipient cells, but growing evidence from EVs in cancer and other processes has expanded the subset of EV functions.^{47, 52-55} Particularly surprising and exciting was the discovery that EV microRNAs can act as ligands for Toll-like receptors (TLR) and induce immune responses or inhibit macrophage activation by suppressing TLR signaling.^{47, 56-59} It is still unclear whether specific microRNAs are actively sorted into EVs, although some microRNAs appear to be selectively targeted to EVs and several mechanisms for selective inclusion of microRNAs have been proposed, as discussed in the section below.

Different microRNA profiles in patients and controls have been reported for many diseases, implicating them in disease pathogenesis.^{43, 46, 50, 60-63} The easy access and stability of EV-microRNAs in biological fluids have created a niche for them as potential diagnostic biomarkers. Even though most of such studies to-date come from cancer research, the brain has the highest expression of tissue-specific microRNAs (70% of all reported microRNAs) and thus microRNAs in brain EVs may also be particularly informative in neurological disorders.^{64, 65}

The presence in EVs of misfolded proteins associated with neurodegenerative disorders [$A\beta$, tau (MAPT), α -synuclein (SNCA), and prion proteins] prompted studies to test a role for EVs in disease propagation.⁶⁶⁻⁶⁹ The discovery of microRNAs in EVs expanded the search for mechanisms of disease pathogenesis implicating dysregulation of endogenous microRNAs.^{66, 68, 70, 71} For example, the EV-resident microRNA miR-193b was implicated in regulating the production of amyloid precursor protein (APP, the precursor of the neurotoxic peptide $A\beta$), perhaps by repressing APP expression.⁷² Interestingly, the levels of soluble miR-193b in the blood of patients with MCI (mild cognitive impairment) and AD were similar to those in controls, but EV miR-193b levels in the blood and cerebrospinal fluid (CSF) of persons with MCI and AD was lower,⁷² suggesting that miR-193b was selectively excluded from these disease-associated populations. Sixteen microRNAs implicated in AD were recovered from patients' EVs, reaching a sensitivity and specificity of 87% and 77% for predicting AD. Another set of seven EV microRNAs showed 83-89% accuracy in predicting AD status and recent reviews showcase various microRNA signatures for AD in different body fluids.⁷³ Six EV microRNAs have been associated with AD by multiple groups; among them, miR191-5b in plasma and serum was particularly informative in the diagnosis of AD.⁷⁴ Likewise, differential microRNA profiles were reported when comparing CSF EVs from Parkinson's disease (PD) and AD patients.⁶²

Age-related microRNA and TLR signaling dysregulation may contribute to other diseases of aging, such as muscular and cardiovascular diseases.⁷⁵⁻⁷⁸ Notably, sarcopenia in older individuals could be associated with microRNA dysregulation, and changes in microRNA signatures in muscle tissues have been observed with aging.^{79, 80}

The potential of EV microRNAs to change gene expression locally and distantly, together with their non-immunogenic nature, further suggests that they hold great potential for therapeutic applications.^{46, 81, 82} An important caveat is the variable stoichiometry in microRNAs contained in EVs.^{83, 84} It is currently unknown whether all EVs in a population contain the same amount of microRNAs or whether some vesicles are selectively loaded with given microRNAs; this information is critical for therapeutic applications, since the successful suppression of a given mRNA depends on the types and concentrations of available microRNAs. Even though therapeutic applications of EV microRNAs are still in their infancy, several successful studies *in vitro* and *in vivo* have been reported. In renal fibrosis, EVs from mesenchymal stem cells were engineered to overexpress the microRNA let-7c and were selectively targeted to damaged kidneys, where they successfully attenuated kidney injury.⁸⁵ Similar approaches based on the EV-mediated delivery of microRNAs have been undertaken for the treatment of cancer and liver disease.^{86, 87} This field is expected to boom with increasing knowledge of the targeted sorting, enrichment and packaging of microRNAs into EVs.

Long noncoding RNA (lncRNA)

This class of noncoding RNAs, defined as being >200 nt, was identified almost three decades ago,⁸⁸ but the advent of high-throughput RNA-Seq has begun to reveal the rich and diverse functions of mammalian lncRNAs.⁸⁹⁻⁹¹ lncRNAs are involved in controlling a

variety of cellular processes, such as chromatin organization, gene transcription, mRNA turnover, protein translation, and assembly of macromolecular complexes.⁹²⁻⁹⁴

Numerous lncRNAs have been found in EVs. In 2014, Gezer *et al.* identified lncRNAs including *MALAT1*, *HOTAIR*, *lincRNAp21*, *GAS5*, *TUG1*, and *ncRNA-CCND1* in EVs derived from human cervical and breast carcinomas (HeLa and MCF-7 cells, respectively) by RT-qPCR analysis.⁹⁵ Each lncRNA had different expression patterns in exosomes compared with cells: *lincRNAp21*, *HOTAIR*, and *ncRNA-CCND1* were highly enriched in EVs even if their expression was very low in cells, while expression of *MALAT1* was very high in both. Following exposure to DNA-damaging agents like bleomycin, *lincRNAp21* and *ncRNA-CCND1* were selectively found in EVs, while other lncRNAs such as *MALAT1*, *HOTAIR*, *GAS5* and *TUG1* were not. These results suggest that some lncRNA may be selectively sorted by as-yet unknown mechanisms that regulate the abundance of lncRNAs in EVs under specific cell conditions.

Other studies using prostate cancer cell lines (PC3, VCaP, LNCaP, DU145) identified lncRNAs enriched in EVs relative to EVs from a normal prostate epithelial line.⁹⁶ These lncRNAs have specific motifs which perfectly complement the seed regions of certain microRNAs, such as let-7 family members (let-7a, let-7b, let-7c, let-7d, let-7e and let-7i), miR-17, miR-18a, miR-20a, miR-93, and miR-106b. The most frequent sequence in this subset of lncRNAs is CCUCCC, which matched perfectly miR-7106-5p, miR-6883-5p, miR-6799-5p, miR-6785-5p, miR-4728-5p, miR-6887-5p, miR-6885-5p, miR-6799-5p, miR-328-5p and, miR-149*. Further analysis revealed that miR-149* was also highly enriched in EVs, but not in cells, leading the authors to suggest that the EV lncRNAs might function as a sponge for EV microRNAs, although it is also possible that lncRNAs may provide a mechanism for loading microRNAs into EVs. In addition, among the lncRNAs in EVs, they found enrichment in transcripts bearing RNA motifs recognized by RBPs ELAVL1 (HuR) and RBMX, prompting the additional hypothesis that specific lncRNA-RBP complexes may capture specific microRNA subsets and target them into exosomes.

Circular RNA (circRNA)

CircRNAs are a highly abundant, heterogeneous class of noncoding regulatory RNAs.⁹⁷⁻¹⁰² Although their biogenesis is not well understood, the splicing machinery is believed to generate most circRNAs via head-to-tail backsplicing.¹⁰³ RBPs like muscleblind (MBL), quaking I 5 (QKI5), and the RNA-editing enzyme ADAR were found to be involved in circRNA biogenesis.^{104, 105} High-throughput RNA sequencing together with computational analysis have identified large numbers of circRNAs in mammalian cells.⁹⁷⁻¹⁰² Unlike linear RNAs, circRNAs have a long half-life because they lack free ends and thus cannot be degraded by exonucleases.^{106, 107} This feature may enable critical transcriptional and posttranscriptional functions of circRNAs. CircRNAs have been shown to sponge some microRNAs and thereby control their function as regulators of mRNA stability and/or translation. For instance, *ciRS-7* sponges and regulates the function of miR-7 and *EICiEIF3J* interacts with the snRNP *U1* and the promoter *EIF3J* to enhance *EIF3J* transcription.¹⁰⁸ *CircMbl* regulates the splicing activity of MBL, controlling *MBL* pre-mRNA processing to mature *MBL* mRNA by competing with the splicing machinery.¹⁰⁹ *CircFoxo3* forms a

complex with CDK2 and p21 that limits the cell cycle-dependent interactions of CDK2 with cyclins A and E.¹¹⁰

Although these functions illustrate the emerging impact by EV-harbored circRNAs on cellular processes and cell fates, the extracellular functions of circRNAs via EVs are not known. Recently, circRNAs were found to be both enriched and stable in cancer EVs, suggesting that they could also potentially be used as cancer biomarkers.¹¹¹ In addition, it has been suggested that EVs could represent a mechanism for circRNA clearance¹¹² and that circRNAs in EVs could constitute potential biomarkers in disease processes as well as therapeutic targets.¹¹³

MECHANISMS FOR SPECIFIC SORTING OF RNAs INTO EVs

Specific subsets of RNAs are selectively mobilized to EVs and in some cases excluded from cells¹¹⁴⁻¹¹⁷. Although the mechanisms responsible for this packaging are not clear, some mechanisms responsible for sorting microRNAs to EVs have been suggested,^{118, 119} as discussed below.

microRNA EXOmotifs

A recent survey using microarray analysis to identify microRNAs in primary T lymphoblasts and derived EVs¹¹⁸ revealed specific subsets of microRNAs and mRNAs differentially present in cells and in EVs. Some microRNAs, including miR-575, miR-451, miR-125a-3p, miR-198, miR-601, and miR-877 were highly abundant in EVs (specifically in exosomes) compared to cells and were named EXOmRNAs, while other microRNAs, including miR-17, miR-29a, let-7a, miR-142-3p, miR-181a, and miR-18a, were highly represented in cells. Comparing the two subsets, the authors found two conserved sequences in the subsets of microRNAs that accumulated in exosomes and not in cells, and termed them EXOmotifs. The EXOmotif GGAG is located in the 3' half of the microRNA, while the EXOmotif C/UCCU/G can exist anywhere on the microRNA. In support of the authors' hypothesis, microRNAs with mutated EXOmotifs could not be exported into exosomes and were stored in cells. The RBP HNRNP (heterogeneous nuclear ribonucleoprotein) A2B1 was found to interact with EXOmRNAs and helped transfer them into exosomes through EXOmotifs. Exosomal HNRNP A2B1 had a larger molecular weight than the cellular HNRNP A2B1 due to the attachment of a ubiquitin-related residue (SUMO) in exosomes, and this modification appeared to be crucial for the sorting of EXOmRNAs to exosomes by HNRNP A2B1. While it has been shown that some specific lncRNAs are highly enriched in EVs compared with cells,⁹⁵ the mechanisms responsible for this preferential mobilization are unknown. Much remains to be elucidated about ribonucleoprotein (RNP) complexes, how they are transported to EVs, and whether RNP complexes dissociate in recipient cells or not.

Relative levels of microRNAs and target mRNAs

Another mechanism to sort microRNAs into EVs was identified while performing microRNA transcriptome analysis of BMDMs (bone marrow-derived macrophages) using TaqMan low-density quantitative PCR (qPCR) arrays.¹¹⁹ A specific pool of microRNAs (including miR-150-5p, miR-146a-5p, miR-320-3p, miR-467-3p, and miR-467f) was

enriched in BMDM-derived exosomes but not in BMDMs, and another pool of microRNAs accumulated in BMDMs but not in exosomes. The different microRNA expression profiles in macrophages and macrophage-derived exosomes were investigated using wild-type cells and cells deficient in *DICER1*, the RNase that cleaves precursor (pre-)microRNAs to form mature microRNAs. Surprisingly, *Dicer1* knockout BMDMs produced EVs with marked deficiencies in microRNA levels, even though the BMDMs themselves showed only modest declines in microRNA levels.¹²³ Interestingly, ectopically changing the levels of microRNAs or the target mRNAs influences the sorting of microRNAs to EVs. This observation was made after artificially increasing the levels of miR-511-3p (which is expressed at low levels in BMDMs) and finding that it disproportionately elevated miR-511-3p levels in EVs and not in BMDMs, while raising the levels of a miR-511-3p sponge bearing miR-511-3p binding sites lowered miR-511-3p levels in EVs. These and other lines of evidence suggest that EVs can function as tools to maintain appropriate levels of microRNAs in cells and thereby preserve homeostasis.

EV RNA IN AGING-RELATED DISEASE

There is growing interest in studying EVs in several disease conditions, including those showing higher incidence in the elderly, such as neurodegenerative diseases and cancer.

Neurodegenerative disease (Parkinson's and Alzheimer's diseases)

Advancing age causes loss in the structure and function of neurons that can lead to neurodegenerative conditions such as Parkinson's disease (PD) and Alzheimer's disease (AD). Efforts are underway to find biomarkers for early detection of these neurodegenerative diseases. Gui and colleagues isolated exosomes in CSF from PD and AD patients and healthy controls by flow cytometry based on the presence of the exosomal surface protein CD63, and used microarray analysis to identify microRNAs with differential abundance among the AD, PD, and normal groups.⁶² Compared with healthy control exosomes, PD exosomes showed that 16 microRNAs were more abundant (including miR-153, miR-409-3p, miR-10a-5p, and let-7g-3p) and 11 were less abundant (including miR-1, miR-19b-3p). AD exosomes showed fewer differences with healthy controls, with only miR-16-2, miR-29c, miR-132-5p, miR-136-3p, miR-331-5p, and miR-485-5p showing significantly altered levels. Further assessment of mRNAs and lncRNAs associated with PD and AD using RT-qPCR analysis revealed several mRNAs differentially expressed in CSF exosomes from PD and AD subjects. For example, compared with healthy CSF exosomes, the levels of *APP* (amyloid precursor protein) mRNA, *SNCA* (α -synuclein) mRNA, *DJ-1/PARK7* mRNA, and *CX3CL1* (Fractalkine) mRNA were lower in AD and PD exosomes, while the levels of *NEFL* (neurofilament L) mRNA was higher in AD and PD CSF exosomes. Interestingly, *MAPT* (Tau) mRNA was unchanged among the three exosome groups, and lncRNAs *RP11-462G22.1* and *PCA3* were enriched in CSF exosomes from PD and AD. Taken together, the authors propose that some of these RNAs could have diagnostic values, although additional analysis is necessary.

Cancer

There is also a great deal of interest in EVs in cancer diagnosis and therapy. In an early study in glioblastoma patients, numerous mRNAs and microRNAs were found to be highly enriched in EVs present in the serum.²⁰ In prostate cancer patients, EVs purified from the urine were found to contain prostate cancer biomarkers (*PCA3* and *TMPRSS2:ERG* mRNAs) by using nested PCR.¹²⁰ More recent studies showed RNAs specifically enriched in EVs from cultured prostate cancer lines PCA3, VCaP, LNCaP, and DU145⁹⁶ relative to exosomes from normal cells, as mentioned above. In ovarian cancer, exosomal RNAs were also identified by several groups. Several of these reports have found exosomal microRNAs, including miR-21, miR-141, miR-182, miR-200a, miR-200b, miR-200c, miR-203, miR-205, and miR-214 as being highly enriched in EVs from ovarian cancer patients.¹²¹⁻¹²⁴ In summary, there are intense efforts to exploit EVs in cancer diagnosis. In addition, new studies have begun to investigate the use of EVs in cancer therapy via the delivery of RNAs and chemotherapeutic drugs.¹²⁵⁻¹²⁷

PERSPECTIVES

The presence of various RNA molecules in EVs is well established,³¹ although the mechanisms that control EV production, release, and uptake by recipient cells are poorly understood. Such mechanisms could be altered under pathological conditions and may provide therapeutic opportunities. Detection of EV RNAs by high-throughput (e.g., RNA-Seq and microarray analyses) or by transcript-specific RT-qPCR analysis has shown that some transcripts are selectively included into EVs and some are specifically excluded from EVs. How the selective localization of EV RNAs is regulated is largely unknown, but it likely involves their recognition by RBPs and the formation of RNP complexes that can regulate RNA uptake and/or retention. Although efforts to identify specific RNA signature sequences that target them for inclusion into EVs or exclusion from EVs have been initiated, additional investigation is needed. Similarly, the RBPs implicated in sorting RNAs to EVs, the signaling pathways that regulate this process, and possible post-translational modifications of the RNPs responsible for sorting EV RNAs are almost entirely unknown.

Another important consideration is whether the various RNA molecules in EVs are intact or partially degraded. This question is particularly important because intact mRNAs could serve as templates for functional proteins in the recipient cells, and full-length noncoding RNAs (including lncRNAs and microRNAs) might potentially retain their original function. Partially degraded mRNAs and ncRNAs, on the other hand, could assume new functions, as sponges or competitors for certain particular factors (e.g., RBPs, microRNAs), in turn affecting cellular processes in different ways. Advances in technical and analytical tools for investigating EV RNAs are needed in order to help elucidate these questions.

Body fluids contain EVs originating from different tissues, but each tissue is expected to release EVs containing distinct subsets of RNAs; for instance, neuronal EVs may have different RNA contents than EVs from other tissues like liver or muscle. Accordingly, identifying the source of EVs is particularly important. In this regard, robust efforts are also underway to identify markers unique to EVs from neurons, liver, pancreas, prostate, breast, muscle, as well as other organs and tissues. Markers can also be informative as to whether

EVs are microvesicles or exosomes, particularly when analyzed in conjunction with EV size assessments.

Finally, EVs can be retooled as delivery vectors for therapeutic intervention.^{125, 126, 128} While an individual's EVs are recognized by the body as 'self' and thus allowed to circulate without rejection by the body's immune system, caution should be to avoid unwanted immune responses triggered by EVs.¹²⁹ With better knowledge of the EV determinants that target uptake by other tissues, EVs could be engineered to deliver therapeutic factors (nucleic acids, proteins, or drugs) to a target tissue. Therefore, it will be especially important to identify the factors that target EVs to a given cell type or tissue, whereupon it can be internalized via mechanisms such as membrane fusion, caveolin-mediated endocytosis, and phagocytosis.¹³⁰ The actual molecular mediators of EV uptake are not known, but ongoing efforts from our laboratory include screening of RNAi libraries to identify proteins implicated in this process. Progressively better understanding of the cargos (particularly RNA molecules) that EVs carry, the factors that govern EV release and uptake, and the tissues that originate and deliver EVs, this important class of intercellular transport vehicles will become increasingly valuable tools in many areas of physiology and pathology.

ACKNOWLEDGEMENTS

This work was supported in its entirety by the National Institute on Aging Intramural Research Program of the National Institutes of Health.

REFERENCES

1. Lo Cicero A, Stahl PD, Raposo G. Extracellular vesicles shuffling intercellular messages: for good or for bad. *Curr Opin Cell Biol.* 35:69–77. [PubMed: 26001269]
2. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. *Nat Rev Immunol.* 2002; 2:569–579. [PubMed: 12154376]
3. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. *Nat Rev Immunol.* 2009; 9:581–593. [PubMed: 19498381]
4. Tannous BA, Kim DE, Fernandez JL, Weissleder R, Breakefield XO. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. *Mol Ther.* 2005; 11:435–443. [PubMed: 15727940]
5. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. *Leukemia.* 2006; 20:1487–1495. [PubMed: 16791265]
6. Muralidharan-Chari V, Clancy JW, Sedgwick A, D'Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. *J Cell Sci.* 123:1603–1611.
7. Hristov M, Erl W, Linder S, Weber PC. Apoptotic bodies from endothelial cells enhance the number and initiate the differentiation of human endothelial progenitor cells in vitro. *Blood.* 2004; 104:2761–2766. [PubMed: 15242875]
8. Kranich J, Krautler NJ, Heinen E, Polymenidou M, Bridel C, Schildknecht A, Huber C, Kosco-Vilbois MH, Zinkernagel R, Miele G, et al. Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8. *J Exp Med.* 2008; 205:1293–1302. [PubMed: 18490487]
9. Pan BT, Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. *Cell.* 1983; 33:967–978. [PubMed: 6307529]
10. Pan BT, Teng K, Wu C, Adam M, Johnstone RM. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. *J Cell Biol.* 1985; 101:942–948. [PubMed: 2993317]

11. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *J Biol Chem.* 1987; 262:9412–9420. [PubMed: 3597417]
12. Admyre C, Johansson SM, Qazi KR, Filen JJ, Laheesmaa R, Norman M, Neve EP, Scheynius A, Gabrielsson S. Exosomes with immune modulatory features are present in human breast milk. *J Immunol.* 2007; 179:1969–1978. [PubMed: 17641064]
13. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. *Proc Natl Acad Sci U S A.* 2004; 101:13368–13373. [PubMed: 15326289]
14. Ogawa Y, Miura Y, Harazono A, Kanai-Azuma M, Akimoto Y, Kawakami H, Yamaguchi T, Toda T, Endo T, Tsubuki M, et al. Proteomic analysis of two types of exosomes in human whole saliva. *Biol Pharm Bull.* 34:13–23.
15. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C. Exosomal-like vesicles are present in human blood plasma. *Int Immunol.* 2005; 17:879–887. [PubMed: 15908444]
16. Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, Skog J. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. *Nat Commun.* 2:180.
17. Hagiwara S, Kantharidis P, Cooper ME. MicroRNA as biomarkers and regulator of cardiovascular development and disease. *Curr Pharm Des.* 20:2347–2370.
18. Ban JJ, Lee M, Im W, Kim M. Low pH increases the yield of exosome isolation. *Biochem Biophys Res Commun.* 461:76–79.
19. Cheng L, Sharples RA, Scicluna BJ, Hill AF. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. *J Extracell Vesicles.* 3
20. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Estevés M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. *Nat Cell Biol.* 2008; 10:1470–1476. [PubMed: 19011622]
21. Lai CP, Kim EY, Badr CE, Weissleder R, Mempel TR, Tannous BA, Breakefield XO. Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. *Nat Commun.* 6:7029. [PubMed: 25967391]
22. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, Ratajczak MZ. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. *Leukemia.* 2006; 20:847–856. [PubMed: 16453000]
23. Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, Illei GG, Alevizos I. Exosomes from human saliva as a source of microRNA biomarkers. *Oral Dis.* 16:34–38.
24. Gupta SK, Bang C, Thum T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. *Circ Cardiovasc Genet.* 3:484–488. [PubMed: 20959591]
25. Arslan F, Lai RC, Smeets MB, Akeroyd L, Choo A, Aguor EN, Timmers L, van Rijen HV, Doevendans PA, Pasterkamp G, et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. *Stem Cell Res.* 10:301–312.
26. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, Bruno S, Bussolati B, Camussi G. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. *Blood.* 2007; 110:2440–2448. [PubMed: 17536014]
27. Sahoo S, Klychko E, Thorne T, Misener S, Schultz KM, Millay M, Ito A, Liu T, Kamide C, Agrawal H, et al. Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity. *Circ Res.* 109:724–728.
28. Katsuda T, Tsuchiya R, Kosaka N, Yoshioka Y, Takagaki K, Oki K, Takeshita F, Sakai Y, Kuroda M, Ochiya T. Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes. *Sci Rep.* 3:1197.
29. Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, Fujita K, Mizutani T, Ohgi T, Ochiya T, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. *Mol Ther.* 21:185–191.

30. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhali S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nat Biotechnol.* 29:341–345.
31. Nolte-t Hoen EN, Buermans HP, Waasdorp M, Stoorvogel W, Wauben MH, t Hoen PA. Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. *Nucleic Acids Res.* 40:9272–9285.
32. Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan ML, Karlsson JM, Baty CJ, Gibson GA, Erdos G, Wang Z, et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. *Blood.* 119:756–766.
33. Hergenreider E, Heydt S, Treguer K, Boettger T, Horrevoets AJ, Zeiher AM, Scheffer MP, Frangakis AS, Yin X, Mayr M, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. *Nat Cell Biol.* 2012; 14:249–256. [PubMed: 22327366]
34. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol.* 2007; 9:654–659. [PubMed: 17486113]
35. Mitsuhashi M, Taub DD, Kapogiannis D, Eitan E, Zukley L, Mattson MP, Ferrucci L, Schwartz JB, Goetzl EJ. Aging enhances release of exosomal cytokine mRNAs by Abeta1-42-stimulated macrophages. *FASEB J.* 2013; 27:5141–5150. [PubMed: 24014820]
36. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. *Cell.* 2009; 136:642–655. [PubMed: 19239886]
37. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. *Nat Rev Mol Cell Biol.* 2005; 6:376–385. [PubMed: 15852042]
38. Tomari Y, Zamore PD. MicroRNA biogenesis: drosha can't cut it without a partner. *Curr Biol.* 2005; 15:R61–64. [PubMed: 15668159]
39. Meister G. Argonaute proteins: functional insights and emerging roles. *Nat Rev Genet.* 2013; 14:447–459. [PubMed: 23732335]
40. Miyoshi K, Miyoshi T, Siomi H. Many ways to generate microRNA-like small RNAs: non-canonical pathways for microRNA production. *Mol Genet Genomics.* 2010; 284:95–103. [PubMed: 20596726]
41. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. *Nat Rev Genet.* 2011; 12:99–110. [PubMed: 21245828]
42. Ameres SL, Zamore PD. Diversifying microRNA sequence and function. *Nat Rev Mol Cell Biol.* 2013; 14:475–488. [PubMed: 23800994]
43. Nishida-Aoki N, Ochiya T. Interactions between cancer cells and normal cells via miRNAs in extracellular vesicles. *Cell Mol Life Sci.* 2015; 72:1849–1861. [PubMed: 25563488]
44. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanian EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al. Circulating microRNAs as stable blood-based markers for cancer detection. *Proc Natl Acad Sci U S A.* 2008; 105:10513–10518. [PubMed: 18663219]
45. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. The microRNA spectrum in 12 body fluids. *Clin Chem.* 2010; 56:1733–1741. [PubMed: 20847327]
46. Bronisz A, Godlewski J, Chiocca EA. Extracellular Vesicles and MicroRNAs: Their Role in Tumorigenicity and Therapy for Brain Tumors. *Cell Mol Neurobiol.* 2016; 36:361–376. [PubMed: 26983830]
47. Iftikhar H, Carney GE. Evidence and potential in vivo functions for biofluid miRNAs: From expression profiling to functional testing: Potential roles of extracellular miRNAs as indicators of physiological change and as agents of intercellular information exchange. *Bioessays.* 2016; 38:367–378. [PubMed: 26934338]
48. Gould SJ, Raposo G. As we wait: coping with an imperfect nomenclature for extracellular vesicles. *J Extracell Vesicles.* 2013; 2
49. Crescitelli R, Lasser C, Szabo TG, Kittel A, Eldh M, Dianzani I, Buzas EI, Lotvall J. Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. *J Extracell Vesicles.* 2013; 2

50. Willms E, Johansson HJ, Mager I, Lee Y, Blomberg KE, Sadik M, Alaarg A, Smith CI, Lehtio J, El Andaloussi S, et al. Cells release subpopulations of exosomes with distinct molecular and biological properties. *Sci Rep*. 2016; 6:22519. [PubMed: 26931825]
51. Hagiwara S, Kantharidis P, Cooper ME. MicroRNA as biomarkers and regulator of cardiovascular development and disease. *Curr Pharm Des*. 2014; 20:2347–2370. [PubMed: 23844813]
52. Morel L, Regan M, Higashimori H, Ng SK, Esau C, Vidensky S, Rothstein J, Yang Y. Neuronal exosomal miRNA-dependent translational regulation of astroglial glutamate transporter GLT1. *J Biol Chem*. 2013; 288:7105–7116. [PubMed: 23364798]
53. Patton JG, Franklin JL, Weaver AM, Vickers K, Zhang B, Coffey RJ, Ansel KM, Blleloch R, Goga A, Huang B, et al. Biogenesis, delivery, and function of extracellular RNA. *J Extracell Vesicles*. 2015; 4:27494. [PubMed: 26320939]
54. Xu J, Chen Q, Zen K, Zhang C, Zhang Q. Synaptosomes secrete and uptake functionally active microRNAs via exocytosis and endocytosis pathways. *J Neurochem*. 2013; 124:15–25. [PubMed: 23083096]
55. Bryniarski K, Ptak W, Martin E, Nazimek K, Szczepanik M, Sanak M, Askenase PW. Free Extracellular miRNA Functionally Targets Cells by Transfecting Exosomes from Their Companion Cells. *PLoS One*. 2015; 10:e0122991. [PubMed: 25923429]
56. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. *Proc Natl Acad Sci U S A*. 2012; 109:E2110–2116. [PubMed: 22753494]
57. Chen X, Liang H, Zhang J, Zen K, Zhang CY. microRNAs are ligands of Toll-like receptors. *RNA*. 2013; 19:737–739. [PubMed: 23554231]
58. Phinney DG, Di Giuseppe M, Njah J, Sala E, Shiva S, St Croix CM, Stolz DB, Watkins SC, Di YP, Leikauf GD, et al. Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs. *Nat Commun*. 2015; 6:8472. [PubMed: 26442449]
59. Alexander M, Hu R, Runtsch MC, Kagele DA, Mosbrugger TL, Tolmachova T, Seabra MC, Round JL, Ward DM, O'Connell RM. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. *Nat Commun*. 2015; 6:7321. [PubMed: 26084661]
60. Akers JC, Ramakrishnan V, Kim R, Phillips S, Kaimal V, Mao Y, Hua W, Yang I, Fu CC, Nolan J, et al. miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. *J Neurooncol*. 2015; 123:205–216. [PubMed: 25903655]
61. Bellingham SA, Coleman BM, Hill AF. Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. *Nucleic Acids Res*. 2012; 40:10937–10949. [PubMed: 22965126]
62. Gui Y, Liu H, Zhang L, Lv W, Hu X. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. *Oncotarget*. 2015; 6:37043–37053. [PubMed: 26497684]
63. Lugli G, Cohen AM, Bennett DA, Shah RC, Fields CJ, Hernandez AG, Smalheiser NR. Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. *PLoS One*. 2015; 10:e0139233. [PubMed: 26426747]
64. Babak T, Zhang W, Morris Q, Blencowe BJ, Hughes TR. Probing microRNAs with microarrays: tissue specificity and functional inference. *RNA*. 2004; 10:1813–1819. [PubMed: 15496526]
65. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. *Genome Biol*. 2004; 5:R13. [PubMed: 15003116]
66. Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. *Proc Natl Acad Sci U S A*. 2006; 103:11172–11177. [PubMed: 16837572]
67. Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S, Jackson B, McKee AC, Alvarez VE, Lee NC, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. *J Biol Chem*. 2012; 287:3842–3849. [PubMed: 22057275]
68. Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner

- by exosomes and impacts neuronal survival. *J Neurosci*. 2010; 30:6838–6851. [PubMed: 20484626]
69. Robertson C, Booth SA, Beniac DR, Coulthart MB, Booth TF, McNicol A. Cellular prion protein is released on exosomes from activated platelets. *Blood*. 2006; 107:3907–3911. [PubMed: 16434486]
 70. Cheng L, Quek CY, Sun X, Bellingham SA, Hill AF. The detection of microRNA associated with Alzheimer's disease in biological fluids using next-generation sequencing technologies. *Front Genet*. 4:150. [PubMed: 23964286]
 71. Cheng L, Quek CY, Sun X, Bellingham SA, Hill AF. The detection of microRNA associated with Alzheimer's disease in biological fluids using next-generation sequencing technologies. *Front Genet*. 2013; 4:150. [PubMed: 23964286]
 72. Liu CG, Song J, Zhang YQ, Wang PC. MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer's disease. *Mol Med Rep*. 2014; 10:2395–2400. [PubMed: 25119742]
 73. Van Giau V, An SS. Emergence of exosomal miRNAs as a diagnostic biomarker for Alzheimer's disease. *J Neurol Sci*. 2016; 360:141–152. [PubMed: 26723991]
 74. Kumar S, Reddy PH. Are circulating microRNAs peripheral biomarkers for Alzheimer's disease? *Biochim Biophys Acta*. 2016; 1862:1617–1627. [PubMed: 27264337]
 75. Murach KA, McCarthy JJ. MicroRNAs, heart failure, and aging: potential interactions with skeletal muscle. *Heart Fail Rev*. 2016
 76. Rodosthenous RS, Coull BA, Lu Q, Vokonas PS, Schwartz JD, Baccarelli AA. Ambient particulate matter and microRNAs in extracellular vesicles: a pilot study of older individuals. *Part Fibre Toxicol*. 2016; 13:13. [PubMed: 26956024]
 77. Pfeifer P, Werner N, Jansen F. Role and Function of MicroRNAs in Extracellular Vesicles in Cardiovascular Biology. *Biomed Res Int*. 2015; 2015:161393. [PubMed: 26558258]
 78. Paschon V, Takada SH, Ikebara JM, Sousa E, Raeisossadati R, Ulrich H, Kihara AH. Interplay Between Exosomes, microRNAs and Toll-Like Receptors in Brain Disorders. *Mol Neurobiol*. 2016; 53:2016–2028. [PubMed: 25862375]
 79. Drummond MJ, McCarthy JJ, Fry CS, Esser KA, Rasmussen BB. Aging differentially affects human skeletal muscle microRNA expression at rest and after an anabolic stimulus of resistance exercise and essential amino acids. *Am J Physiol Endocrinol Metab*. 2008; 295:E1333–1340. [PubMed: 18827171]
 80. Drummond MJ, McCarthy JJ, Sinha M, Spratt HM, Volpi E, Esser KA, Rasmussen BB. Aging and microRNA expression in human skeletal muscle: a microarray and bioinformatics analysis. *Physiol Genomics*. 43:595–603. [PubMed: 20876843]
 81. Sato-Kuwabara Y, Melo SA, Soares FA, Calin GA. The fusion of two worlds: non-coding RNAs and extracellular vesicles--diagnostic and therapeutic implications (Review). *Int J Oncol*. 2015; 46:17–27. [PubMed: 25338714]
 82. Kinoshita T, Yip KW, Spence T, Liu FF. MicroRNAs in extracellular vesicles: potential cancer biomarkers. *J Hum Genet*. 2016
 83. Stevanato L, Thanabalasundaram L, Vysokov N, Sinden JD. Investigation of Content, Stoichiometry and Transfer of miRNA from Human Neural Stem Cell Line Derived Exosomes. *PLoS One*. 2016; 11:e0146353. [PubMed: 26752061]
 84. Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, Cheng HH, Arroyo JD, Meredith EK, Gallichotte EN, et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. *Proc Natl Acad Sci U S A*. 2014; 111:14888–14893. [PubMed: 25267620]
 85. Wang B, Yao K, Huuskens BM, Shen HH, Zhuang J, Godson C, Brennan EP, Wilkinson-Berka JL, Wise AF, Ricardo SD. Mesenchymal Stem Cells Deliver Exogenous MicroRNA-let7c via Exosomes to Attenuate Renal Fibrosis. *Mol Ther*. 2016; 24:1290–1301. [PubMed: 27203438]
 86. Fatima F, Nawaz M. Stem cell-derived exosomes: roles in stromal remodeling, tumor progression, and cancer immunotherapy. *Chin J Cancer*. 2015; 34:541–553. [PubMed: 26369565]
 87. Momen-Heravi F, Bala S, Kodys K, Szabo G. Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and sensitize monocytes to LPS. *Sci Rep*. 2015; 5:9991. [PubMed: 25973575]

88. Pachnis V, Brannan CI, Tilghman SM. The structure and expression of a novel gene activated in early mouse embryogenesis. *EMBO J.* 1988; 7:673–681. [PubMed: 3396539]
89. Kretz M, Sitrashvili Z, Chu C, Webster DE, Zehnder A, Qu K, Lee CS, Flockhart RJ, Groff AF, Chow J, et al. Control of somatic tissue differentiation by the long non-coding RNA TINCR. *Nature.* 2013; 493:231–235. [PubMed: 23201690]
90. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, Presser A, Bernstein BE, van Oudenaarden A, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. *Proc Natl Acad Sci U S A.* 2009; 106:11667–11672. [PubMed: 19571010]
91. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Bruggmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. *Cell.* 2007; 129:1311–1323. [PubMed: 17604720]
92. Kino T, Hurt DE, Ichijo T, Nader N, Chrousos GP. Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. *Sci Signal.* 2010; 3:ra8. [PubMed: 20124551]
93. Ng SY, Johnson R, Stanton LW. Human long non-coding RNAs promote pluripotency and neuronal differentiation by association with chromatin modifiers and transcription factors. *EMBO J.* 2012; 31:522–533. [PubMed: 22193719]
94. Martianov I, Ramadass A, Serra Barros A, Chow N, Akoulitchev A. Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript. *Nature.* 2007; 445:666–670. [PubMed: 17237763]
95. Gezer U, Ozgur E, Cetinkaya M, Isin M, Dalay N. Long non-coding RNAs with low expression levels in cells are enriched in secreted exosomes. *Cell Biol Int.* 38:1076–1079.
96. Ahadi A, Brennan S, Kennedy PJ, Hutvagner G, Tran N. Long non-coding RNAs harboring miRNA seed regions are enriched in prostate cancer exosomes. *Sci Rep.* 6:24922.
97. Salzman J, Chen RE, Olsen MN, Wang PL, Brown PO. Cell-type specific features of circular RNA expression. *PLoS Genet.* 9:e1003777.
98. Rybak-Wolf A, Stottmeister C, Glazar P, Jens M, Pino N, Giusti S, Hanan M, Behm M, Bartok O, Ashwal-Fluss R, et al. Circular RNAs in the Mammalian Brain Are Highly Abundant, Conserved, and Dynamically Expressed. *Mol Cell.* 58:870–885. [PubMed: 25921068]
99. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, Sharpless NE. Circular RNAs are abundant, conserved, and associated with ALU repeats. *RNA.* 19:141–157.
100. Glazar P, Papavasileiou P, Rajewsky N. circBase: a database for circular RNAs. *RNA.* 20:1666–1670.
101. Abdelmohsen K, Panda AC, De S, Grammatikakis I, Kim J, Ding J, Noh JH, Kim KM, Mattison JA, de Cabo R, et al. Circular RNAs in monkey muscle: age-dependent changes. *Aging (Albany NY).* 7:903–910. [PubMed: 26546448]
102. Guo JU, Agarwal V, Guo H, Bartel DP. Expanded identification and characterization of mammalian circular RNAs. *Genome Biol.* 15:409.
103. Wilusz JE, Sharp PA. Molecular biology. A circuitous route to noncoding RNA. *Science.* 340:440–441. [PubMed: 23620042]
104. Conn SJ, Pillman KA, Toubia J, Conn VM, Salmanidis M, Phillips CA, Roslan S, Schreiber AW, Gregory PA, Goodall GJ. The RNA binding protein quaking regulates formation of circRNAs. *Cell.* 160:1125–1134.
105. Chen T, Xiang JF, Zhu S, Chen S, Yin QF, Zhang XO, Zhang J, Feng H, Dong R, Li XJ, et al. ADAR1 is required for differentiation and neural induction by regulating microRNA processing in a catalytically independent manner. *Cell Res.* 25:459–476.
106. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J. Natural RNA circles function as efficient microRNA sponges. *Nature.* 495:384–388. [PubMed: 23446346]
107. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature.* 495:333–338. [PubMed: 23446348]

108. Bellingham SA, Guo BB, Coleman BM, Hill AF. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? *Front Physiol.* 3:124. [PubMed: 22563321]
109. Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, Evantal N, Memczak S, Rajewsky N, Kadener S. circRNA biogenesis competes with pre-mRNA splicing. *Mol Cell.* 2014; 56:55–66. [PubMed: 25242144]
110. Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, Evantal N, Memczak S, Rajewsky N, Kadener S. circRNA biogenesis competes with pre-mRNA splicing. *Mol Cell.* 56:55–66. [PubMed: 25242144]
111. Du WW, Yang W, Liu E, Yang Z, Dhaliwal P, Yang BB. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. *Nucleic Acids Res.* 44:2846–2858.
112. Lasda E, Parker R. Circular RNAs Co-Precipitate with Extracellular Vesicles: A Possible Mechanism for circRNA Clearance. *PLoS One.* 2016; 11:e0148407. [PubMed: 26848835]
113. Bao C, Lyu D, Huang S. Circular RNA expands its territory. *Mol Cell Oncol.* 2016; 3:e1084443. [PubMed: 27308606]
114. Manterola L, Guruceaga E, Gallego Perez-Larraya J, Gonzalez-Huarriz M, Jauregui P, Tejada S, Diez-Valle R, Segura V, Sampron N, Barrena C, et al. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. *Neuro Oncol.* 2014; 16:520–527. [PubMed: 24435880]
115. Batagov AO, Kurochkin IV. Exosomes secreted by human cells transport largely mRNA fragments that are enriched in the 3'-untranslated regions. *Biol Direct.* 2013; 8:12. [PubMed: 23758897]
116. Vojtech L, Woo S, Hughes S, Levy C, Ballweber L, Sauteraud RP, Strobl J, Westerberg K, Gottardo R, Tewari M, et al. Exosomes in human semen carry a distinctive repertoire of small non-coding RNAs with potential regulatory functions. *Nucleic Acids Res.* 2014; 42:7290–7304. [PubMed: 24838567]
117. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, Gonzalez S, Sanchez-Cabo F, Gonzalez MA, Bernad A, Sanchez-Madrid F. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. *Nat Commun.* 2011; 2:282. [PubMed: 21505438]
118. Villarroya-Beltri C, Gutierrez-Vazquez C, Sanchez-Cabo F, Perez-Hernandez D, Vazquez J, Martin-Cofreces N, Martinez-Herrera DJ, Pascual-Montano A, Mittelbrunn M, Sanchez-Madrid F. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. *Nat Commun.* 4:2980.
119. Squadrito ML, Baer C, Burdet F, Maderna C, Gilfillan GD, Lyle R, Ibberson M, De Palma M. Endogenous RNAs modulate microRNA sorting to exosomes and transfer to acceptor cells. *Cell Rep.* 2014; 8:1432–1446. [PubMed: 25159140]
120. Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, Widmark A. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. *Br J Cancer.* 2009; 100:1603–1607. [PubMed: 19401683]
121. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. *Gynecol Oncol.* 2008; 110:13–21. [PubMed: 18589210]
122. Zuberi M, Mir R, Das J, Ahmad I, Javid J, Yadav P, Masroor M, Ahmad S, Ray PC, Saxena A. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features. *Clin Transl Oncol.* 2015; 17:779–787. [PubMed: 26063644]
123. Gao YC, Wu J. MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer. *Tumour Biol.* 2015; 36:4843–4850. [PubMed: 25636451]
124. Langhe R, Norris L, Saadeh FA, Blackshields G, Varley R, Harrison A, Gleeson N, Spillane C, Martin C, O'Donnell DM, et al. A novel serum microRNA panel to discriminate benign from malignant ovarian disease. *Cancer Lett.* 2015; 356:628–636. [PubMed: 25451316]
125. Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, Wei J, Nie G. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. *Biomaterials.* 2014; 35:2383–2390. [PubMed: 24345736]

126. Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, Yin VP, Lockman P, Bai S. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. *Pharm Res.* 2015; 32:2003–2014. [PubMed: 25609010]
127. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. *Nat Med.* 1998; 4:594–600. [PubMed: 9585234]
128. Shen C, Hao SG, Zhao CX, Zhu J, Wang C. Antileukaemia immunity: effect of exosomes against NB4 acute promyelocytic leukaemia cells. *J Int Med Res.* 2011; 39:740–747. [PubMed: 21819704]
129. Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. *Nat Rev Immunol.* 2014; 14:195–208. [PubMed: 24566916]
130. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. *J Extracell Vesicles.* Aug 4.2014 :3.




Figure 1. Different Types of Extracellular Vesicles

Schematic depiction of the distinct sizes, contents, and detection markers for exosomes (*left*), microvesicles (*middle*), and apoptotic bodies (*right*).

Table 1**EV RNAs**

Types of RNAs identified in EVs, including coding RNAs (mRNA) and noncoding RNAs (microRNAs, lncRNAs, circRNAs). Disease processes in which EV RNAs are differentially enriched or excluded, forms of EV purification, and methods of EV RNA detection are indicated.

EV RNA		Altered levels in EVs from aging-related disease	EV Purification	Detection	Refs.				
Protein-coding RNA	mRNA	<i>NEFL</i>	ultracentrifugation	qPCR validation	[62]				
		<i>APP</i>							
		<i>SNCA</i>							
		<i>DJ-1/PARK7</i>							
		<i>Fractalkine/CX3CL1</i>							
		<i>PCA3</i>				enriched in prostate cancer EVs	nested PCR	[120]	
		<i>TMPRSS2: ERG</i>							
	<i>Tau/MAPT</i>	lower in AD EVs	qPCR validation	[62]					
Noncoding RNA	microRNA	miR-153	ultracentrifugation	TaqMan microRNA array qPCR validation	[62]				
		miR-409-3p							
		miR-10a-5p							
		let-7g-3p							
		miR-1				lower in PD EVs			
		miR-19b-3p							
		miR-132-5p				enriched in AD			
		miR-485-5p							
		miR-29c				lower in AD EVs			
		miR-136-3p							
		miR-16-2							
		miR-331-5p							
		miR-21				enriched in ovarian cancer EVs	magnetic activated cell sorting (MACS), anti-epithelial cell adhesion molecule (EpCAM)	microRNA microarray	[121] [121] [124] [121]
		miR-141							
	miR-200a								
	miR-200b								
	miR-200c								
	miR-203								
	miR-205								
	miR-214								
	miR-182								
	lncRNA	<i>RP11-462G22.1</i>	ultracentrifugation	qPCR validation	[62]				
<i>PCA3</i>									
<i>ENST00000501280</i>		enriched in prostate cancer EVs				lncRNA array	[96]		
<i>uc010bys.1</i>									

EV RNA		Altered levels in EVs from aging-related disease	EV Purification	Detection	Refs.	
		<i>uc001qgn.1</i>				
		<i>ENST00000499690</i>				
		<i>ENST00000453968</i>				
		<i>G36642</i>				
		<i>AK055500</i>				
		<i>HIT000070262</i>				
		<i>ENST00000452932</i>				
	circRNA	<i>Circ-CDYL</i>	MHCC-LM3 liver cancer cell EVs	ultracentrifugation	RNA-seq, qPCR validation	[111]
		<i>Circ-CAMSAP1</i>				
		<i>Circ-EZH2</i>				
		<i>Circ-FOXK2</i>				
		<i>Circ-XPO1</i>				
		<i>Circ-KLDHC10</i>	colorectal cancer EVs			

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript